Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Citius Pharmaceuticals, Inc. - Common Stock
(NQ:
CTXR
)
0.5451
-0.0123 (-2.21%)
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Citius Pharmaceuticals, Inc. - Common Stock
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Is ‘One to Watch’
August 25, 2026
Via
Investor Brand Network
Citius Pharmaceuticals (NASDAQ: CTXR) Eyes $400M Market Opportunity with LYMPHIR Launch
October 16, 2025
Via
AB Newswire
Topics
Economy
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
July 18, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second...
Via
Newsfile
Analysts Hunt for Undervalued Biotech Stocks
July 17, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first...
Via
Newsfile
Topics
Economy
Initial Public Offering
Citius Pharmaceuticals (NASDAQ: CTXR) Spearheads the Global Cancer Immunotherapy Market
May 07, 2022
Via
Get News
Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
July 17, 2024
Via
AB Newswire
Bloodstream Infections - From Threats to Solutions
July 11, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second...
Via
Newsfile
Topics
Death
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
July 11, 2024
Via
AB Newswire
Biopharma Stocks Transformative Innovation for the Future of Health
July 11, 2024
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first...
Via
Newsfile
Topics
Artificial Intelligence
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Featured in Coverage of the EF Hutton Annual Global Conference
May 16, 2024
Via
Investor Brand Network
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
November 14, 2023
Via
ACCESSWIRE
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is Specializing in Stem Cell Therapy & Critical Cancer Care Immunotherapy
May 11, 2022
Via
Get News
Citius Pharmaceuticals, Inc is helping Global Cancer Immunotherapy to reach the Market Cap of 152 Billion by 2024.
May 04, 2022
Via
AB Newswire
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
May 03, 2021
Via
FinancialNewsMedia
Topics
Death
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
